| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 93 | 2025 | 1038 | 18.330 |
Why?
|
| Tissue and Organ Procurement | 33 | 2023 | 224 | 10.400 |
Why?
|
| Tissue Donors | 34 | 2024 | 494 | 8.710 |
Why?
|
| Waiting Lists | 31 | 2024 | 227 | 7.140 |
Why?
|
| End Stage Liver Disease | 25 | 2024 | 181 | 6.600 |
Why?
|
| Kidney Transplantation | 16 | 2025 | 643 | 5.840 |
Why?
|
| Graft Survival | 37 | 2025 | 536 | 5.300 |
Why?
|
| Graft Rejection | 17 | 2025 | 590 | 4.380 |
Why?
|
| Organ Transplantation | 11 | 2025 | 167 | 3.630 |
Why?
|
| Transplant Recipients | 12 | 2025 | 216 | 3.260 |
Why?
|
| Donor Selection | 9 | 2024 | 55 | 2.930 |
Why?
|
| Retrospective Studies | 84 | 2025 | 16314 | 2.910 |
Why?
|
| Heart Transplantation | 9 | 2024 | 855 | 2.730 |
Why?
|
| Length of Stay | 9 | 2024 | 1310 | 2.580 |
Why?
|
| Liver Neoplasms | 24 | 2024 | 1312 | 2.560 |
Why?
|
| Allografts | 17 | 2025 | 191 | 2.540 |
Why?
|
| Lung Transplantation | 5 | 2024 | 321 | 2.470 |
Why?
|
| Risk Factors | 49 | 2025 | 10270 | 2.460 |
Why?
|
| Liver Failure | 6 | 2017 | 89 | 2.360 |
Why?
|
| Registries | 10 | 2023 | 1424 | 2.050 |
Why?
|
| Carcinoma, Hepatocellular | 17 | 2023 | 931 | 1.780 |
Why?
|
| Survival Rate | 19 | 2022 | 2044 | 1.780 |
Why?
|
| Humans | 149 | 2025 | 124596 | 1.610 |
Why?
|
| Adolescent | 42 | 2025 | 19280 | 1.380 |
Why?
|
| Child | 46 | 2025 | 24375 | 1.340 |
Why?
|
| Child, Preschool | 34 | 2025 | 14009 | 1.310 |
Why?
|
| Clinical Decision-Making | 3 | 2021 | 266 | 1.310 |
Why?
|
| Intention to Treat Analysis | 3 | 2024 | 64 | 1.280 |
Why?
|
| Adult | 54 | 2025 | 29438 | 1.220 |
Why?
|
| Male | 79 | 2025 | 61192 | 1.210 |
Why?
|
| Drug Overdose | 2 | 2020 | 66 | 1.180 |
Why?
|
| Decision Support Techniques | 4 | 2019 | 292 | 1.110 |
Why?
|
| Female | 73 | 2025 | 66485 | 1.110 |
Why?
|
| Infant | 30 | 2025 | 12469 | 1.080 |
Why?
|
| Hypernatremia | 2 | 2024 | 29 | 1.080 |
Why?
|
| United States | 31 | 2024 | 10887 | 1.070 |
Why?
|
| Hepatoblastoma | 4 | 2023 | 179 | 1.070 |
Why?
|
| Treatment Outcome | 35 | 2025 | 12322 | 1.060 |
Why?
|
| Middle Aged | 46 | 2025 | 26714 | 1.060 |
Why?
|
| Age Factors | 9 | 2024 | 2818 | 1.050 |
Why?
|
| Follow-Up Studies | 23 | 2022 | 5145 | 1.010 |
Why?
|
| Severity of Illness Index | 15 | 2024 | 2891 | 1.000 |
Why?
|
| Living Donors | 8 | 2024 | 111 | 0.990 |
Why?
|
| Postoperative Complications | 13 | 2025 | 3065 | 0.970 |
Why?
|
| Liver Diseases, Alcoholic | 3 | 2023 | 57 | 0.970 |
Why?
|
| Liver | 12 | 2025 | 1739 | 0.890 |
Why?
|
| Healthcare Disparities | 4 | 2021 | 429 | 0.890 |
Why?
|
| Kidney Failure, Chronic | 6 | 2024 | 879 | 0.880 |
Why?
|
| Prognosis | 16 | 2025 | 4626 | 0.860 |
Why?
|
| Pancreas Transplantation | 1 | 2023 | 38 | 0.840 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2024 | 1032 | 0.840 |
Why?
|
| Transplantation | 2 | 2019 | 27 | 0.810 |
Why?
|
| Databases, Factual | 9 | 2025 | 1177 | 0.810 |
Why?
|
| Biliary Atresia | 2 | 2023 | 190 | 0.790 |
Why?
|
| Multivariate Analysis | 9 | 2024 | 1428 | 0.790 |
Why?
|
| Risk Assessment | 10 | 2024 | 3441 | 0.780 |
Why?
|
| Health Facilities | 2 | 2019 | 60 | 0.780 |
Why?
|
| Models, Theoretical | 2 | 2015 | 358 | 0.760 |
Why?
|
| Young Adult | 21 | 2022 | 9014 | 0.760 |
Why?
|
| Logistic Models | 7 | 2024 | 1805 | 0.760 |
Why?
|
| Liver Cirrhosis | 10 | 2023 | 831 | 0.750 |
Why?
|
| Cold Ischemia | 2 | 2018 | 20 | 0.700 |
Why?
|
| Time Factors | 12 | 2025 | 6292 | 0.700 |
Why?
|
| Cystic Fibrosis | 2 | 2020 | 257 | 0.690 |
Why?
|
| Blood Group Incompatibility | 3 | 2018 | 27 | 0.680 |
Why?
|
| Machine Learning | 1 | 2023 | 250 | 0.680 |
Why?
|
| Hospitalization | 3 | 2020 | 1777 | 0.670 |
Why?
|
| ABO Blood-Group System | 3 | 2018 | 66 | 0.670 |
Why?
|
| Learning Curve | 1 | 2020 | 53 | 0.660 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2017 | 74 | 0.640 |
Why?
|
| Infant, Newborn | 16 | 2024 | 8190 | 0.640 |
Why?
|
| Proportional Hazards Models | 9 | 2022 | 1350 | 0.630 |
Why?
|
| Alcohol Abstinence | 1 | 2019 | 16 | 0.630 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2018 | 40 | 0.620 |
Why?
|
| Liver Diseases | 3 | 2022 | 366 | 0.620 |
Why?
|
| Transplantation, Homologous | 7 | 2022 | 661 | 0.600 |
Why?
|
| Aged | 23 | 2024 | 19703 | 0.580 |
Why?
|
| Survival Analysis | 12 | 2021 | 1496 | 0.580 |
Why?
|
| Critical Care | 3 | 2021 | 657 | 0.580 |
Why?
|
| Portal Vein | 3 | 2018 | 94 | 0.580 |
Why?
|
| Suicide | 1 | 2020 | 170 | 0.570 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 31 | 0.550 |
Why?
|
| Narcotics | 1 | 2017 | 63 | 0.550 |
Why?
|
| Blood Loss, Surgical | 2 | 2019 | 154 | 0.530 |
Why?
|
| Alcoholism | 1 | 2019 | 231 | 0.530 |
Why?
|
| Malnutrition | 1 | 2019 | 205 | 0.510 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 1140 | 0.500 |
Why?
|
| Kidney | 6 | 2023 | 1358 | 0.500 |
Why?
|
| Quality Improvement | 1 | 2021 | 640 | 0.500 |
Why?
|
| Patient Selection | 6 | 2020 | 693 | 0.490 |
Why?
|
| Reoperation | 3 | 2018 | 832 | 0.480 |
Why?
|
| Models, Statistical | 1 | 2017 | 471 | 0.470 |
Why?
|
| Endpoint Determination | 1 | 2015 | 56 | 0.470 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 728 | 0.460 |
Why?
|
| Cause of Death | 4 | 2019 | 473 | 0.460 |
Why?
|
| Medical Futility | 1 | 2014 | 37 | 0.450 |
Why?
|
| Neoadjuvant Therapy | 4 | 2020 | 337 | 0.440 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2023 | 672 | 0.440 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 871 | 0.430 |
Why?
|
| Sodium | 4 | 2024 | 295 | 0.430 |
Why?
|
| Hyponatremia | 2 | 2024 | 72 | 0.390 |
Why?
|
| Hepatectomy | 1 | 2013 | 112 | 0.390 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 96 | 0.380 |
Why?
|
| Heart Failure | 3 | 2020 | 2283 | 0.370 |
Why?
|
| Altruism | 2 | 2010 | 24 | 0.370 |
Why?
|
| Cohort Studies | 6 | 2022 | 4795 | 0.360 |
Why?
|
| Cholangiocarcinoma | 1 | 2012 | 106 | 0.360 |
Why?
|
| Blood Transfusion | 1 | 2013 | 309 | 0.360 |
Why?
|
| Vascular Grafting | 3 | 2019 | 46 | 0.330 |
Why?
|
| Health Services Accessibility | 3 | 2021 | 606 | 0.330 |
Why?
|
| Perioperative Care | 3 | 2021 | 195 | 0.330 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 4 | 2022 | 395 | 0.330 |
Why?
|
| Acute-On-Chronic Liver Failure | 2 | 2021 | 64 | 0.320 |
Why?
|
| Ablation Techniques | 2 | 2020 | 31 | 0.320 |
Why?
|
| Hepatitis C | 2 | 2023 | 366 | 0.310 |
Why?
|
| Hepatitis C, Chronic | 2 | 2023 | 325 | 0.310 |
Why?
|
| Lithotripsy | 1 | 2008 | 22 | 0.290 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2008 | 19 | 0.290 |
Why?
|
| Pyelonephritis | 1 | 2008 | 26 | 0.290 |
Why?
|
| Embolism, Air | 1 | 2008 | 24 | 0.290 |
Why?
|
| Gift Giving | 1 | 2008 | 18 | 0.290 |
Why?
|
| Organ Preservation | 2 | 2025 | 45 | 0.280 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2020 | 225 | 0.280 |
Why?
|
| Perfusion | 2 | 2025 | 203 | 0.270 |
Why?
|
| Death | 2 | 2020 | 69 | 0.270 |
Why?
|
| Geography | 2 | 2018 | 113 | 0.270 |
Why?
|
| Reperfusion Injury | 2 | 2025 | 101 | 0.260 |
Why?
|
| Erythrocyte Transfusion | 3 | 2019 | 129 | 0.260 |
Why?
|
| Islets of Langerhans Transplantation | 3 | 2013 | 31 | 0.260 |
Why?
|
| Immunosuppressive Agents | 5 | 2021 | 647 | 0.250 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 2154 | 0.240 |
Why?
|
| Creatinine | 2 | 2025 | 390 | 0.240 |
Why?
|
| Odds Ratio | 2 | 2021 | 1254 | 0.230 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 869 | 0.220 |
Why?
|
| Health Care Rationing | 2 | 2021 | 58 | 0.210 |
Why?
|
| Sex Factors | 2 | 2025 | 1280 | 0.210 |
Why?
|
| Acute Disease | 2 | 2016 | 1110 | 0.210 |
Why?
|
| Histocompatibility Testing | 1 | 2023 | 148 | 0.200 |
Why?
|
| Alcohol Drinking | 2 | 2023 | 343 | 0.200 |
Why?
|
| Postoperative Period | 2 | 2020 | 333 | 0.200 |
Why?
|
| Hemochromatosis | 1 | 2022 | 32 | 0.200 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2022 | 27 | 0.190 |
Why?
|
| HLA Antigens | 1 | 2023 | 244 | 0.190 |
Why?
|
| Iliac Vein | 2 | 2019 | 34 | 0.190 |
Why?
|
| Glomerular Filtration Rate | 4 | 2018 | 503 | 0.190 |
Why?
|
| Bayes Theorem | 1 | 2023 | 284 | 0.190 |
Why?
|
| Stroke Volume | 1 | 2024 | 487 | 0.190 |
Why?
|
| United Kingdom | 2 | 2019 | 189 | 0.180 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2021 | 47 | 0.180 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2023 | 65 | 0.180 |
Why?
|
| Fatty Liver | 2 | 2013 | 184 | 0.180 |
Why?
|
| Transplants | 1 | 2021 | 35 | 0.180 |
Why?
|
| Coinfection | 1 | 2023 | 169 | 0.180 |
Why?
|
| Aftercare | 2 | 2019 | 147 | 0.180 |
Why?
|
| Protective Factors | 1 | 2021 | 85 | 0.180 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 460 | 0.180 |
Why?
|
| Ventricular Function, Left | 1 | 2024 | 506 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2023 | 371 | 0.170 |
Why?
|
| Thrombosis | 2 | 2022 | 520 | 0.170 |
Why?
|
| Multiple Organ Failure | 1 | 2021 | 141 | 0.170 |
Why?
|
| Epidemics | 1 | 2020 | 54 | 0.160 |
Why?
|
| Chickenpox Vaccine | 1 | 2019 | 13 | 0.160 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2019 | 13 | 0.160 |
Why?
|
| Rituximab | 1 | 2020 | 157 | 0.160 |
Why?
|
| Operative Time | 3 | 2019 | 171 | 0.160 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2019 | 43 | 0.160 |
Why?
|
| Linear Models | 3 | 2018 | 671 | 0.160 |
Why?
|
| Tracheostomy | 1 | 2021 | 192 | 0.160 |
Why?
|
| Pandemics | 3 | 2023 | 1099 | 0.160 |
Why?
|
| ROC Curve | 1 | 2021 | 569 | 0.160 |
Why?
|
| Hepatic Artery | 1 | 2019 | 52 | 0.160 |
Why?
|
| Eligibility Determination | 1 | 2019 | 37 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2020 | 174 | 0.150 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 196 | 0.150 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 1231 | 0.150 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 103 | 0.150 |
Why?
|
| Iliac Artery | 1 | 2019 | 93 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 293 | 0.150 |
Why?
|
| Celiac Artery | 1 | 2018 | 33 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2021 | 227 | 0.150 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 128 | 0.150 |
Why?
|
| Incidence | 5 | 2019 | 3138 | 0.150 |
Why?
|
| Hypertension, Portal | 1 | 2018 | 78 | 0.140 |
Why?
|
| Cystatin C | 1 | 2018 | 59 | 0.140 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 85 | 0.140 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2017 | 8 | 0.140 |
Why?
|
| Ectodermal Dysplasia | 1 | 2017 | 45 | 0.140 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 238 | 0.140 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 46 | 0.140 |
Why?
|
| Emergencies | 1 | 2018 | 171 | 0.140 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2017 | 59 | 0.140 |
Why?
|
| Intraoperative Complications | 1 | 2018 | 172 | 0.140 |
Why?
|
| Everolimus | 1 | 2017 | 47 | 0.130 |
Why?
|
| Drowning | 1 | 2017 | 41 | 0.130 |
Why?
|
| Calcineurin Inhibitors | 1 | 2017 | 29 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.130 |
Why?
|
| Critical Illness | 2 | 2021 | 603 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2023 | 852 | 0.130 |
Why?
|
| Acute Kidney Injury | 2 | 2023 | 636 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2050 | 0.130 |
Why?
|
| Hospitals | 1 | 2018 | 388 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2019 | 489 | 0.120 |
Why?
|
| Bone and Bones | 1 | 2017 | 266 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 236 | 0.120 |
Why?
|
| Craniosynostoses | 1 | 2017 | 133 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 1758 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3424 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 2876 | 0.120 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 225 | 0.120 |
Why?
|
| Brain Diseases | 1 | 2018 | 299 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 358 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 372 | 0.120 |
Why?
|
| Lung | 1 | 2022 | 1491 | 0.110 |
Why?
|
| Risk | 1 | 2016 | 755 | 0.110 |
Why?
|
| Metabolomics | 1 | 2017 | 422 | 0.110 |
Why?
|
| California | 1 | 2014 | 128 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2017 | 490 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 6533 | 0.110 |
Why?
|
| Validation Studies as Topic | 1 | 2013 | 13 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1484 | 0.110 |
Why?
|
| Pathology, Surgical | 1 | 2013 | 19 | 0.100 |
Why?
|
| Pancreatitis, Chronic | 1 | 2013 | 68 | 0.100 |
Why?
|
| Transfusion Reaction | 1 | 2013 | 42 | 0.100 |
Why?
|
| Pancreatectomy | 1 | 2013 | 137 | 0.100 |
Why?
|
| Warm Ischemia | 1 | 2013 | 19 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2017 | 480 | 0.100 |
Why?
|
| Abdomen | 1 | 2013 | 127 | 0.100 |
Why?
|
| Bilirubin | 1 | 2013 | 123 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2016 | 541 | 0.100 |
Why?
|
| Robotics | 1 | 2013 | 108 | 0.100 |
Why?
|
| Hepacivirus | 2 | 2023 | 243 | 0.090 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 183 | 0.090 |
Why?
|
| Sarcoma | 1 | 2013 | 183 | 0.090 |
Why?
|
| HIV Infections | 1 | 2023 | 1892 | 0.090 |
Why?
|
| Bile Duct Neoplasms | 1 | 2012 | 108 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1014 | 0.090 |
Why?
|
| Policy | 2 | 2023 | 35 | 0.090 |
Why?
|
| Disease Progression | 3 | 2022 | 2047 | 0.090 |
Why?
|
| Tacrolimus | 2 | 2021 | 99 | 0.090 |
Why?
|
| Heart-Assist Devices | 1 | 2019 | 1021 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2016 | 1561 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2020 | 230 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2014 | 1021 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2009 | 137 | 0.080 |
Why?
|
| Anastomosis, Surgical | 2 | 2019 | 173 | 0.080 |
Why?
|
| Clinical Protocols | 2 | 2020 | 240 | 0.070 |
Why?
|
| New York City | 1 | 2008 | 59 | 0.070 |
Why?
|
| Antiviral Agents | 2 | 2023 | 748 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2009 | 406 | 0.070 |
Why?
|
| Program Development | 1 | 2008 | 186 | 0.070 |
Why?
|
| Neutrophils | 1 | 2009 | 381 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1108 | 0.070 |
Why?
|
| Diverticulum | 1 | 2005 | 28 | 0.060 |
Why?
|
| Duodenal Diseases | 1 | 2005 | 34 | 0.060 |
Why?
|
| Primary Graft Dysfunction | 1 | 2025 | 24 | 0.060 |
Why?
|
| Biopsy | 2 | 2021 | 1237 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 947 | 0.050 |
Why?
|
| Ascites | 1 | 2023 | 88 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 242 | 0.050 |
Why?
|
| Hepatic Encephalopathy | 1 | 2023 | 75 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2021 | 6135 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1162 | 0.050 |
Why?
|
| Integrases | 1 | 2023 | 158 | 0.050 |
Why?
|
| HIV | 1 | 2023 | 180 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 24 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 841 | 0.050 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2021 | 26 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2021 | 87 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 144 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 317 | 0.040 |
Why?
|
| Organ Dysfunction Scores | 1 | 2020 | 48 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 171 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 275 | 0.040 |
Why?
|
| Public Opinion | 1 | 2020 | 56 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 212 | 0.040 |
Why?
|
| Attitude | 1 | 2020 | 115 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 245 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2013 | 299 | 0.040 |
Why?
|
| Transplantation, Heterotopic | 1 | 2019 | 29 | 0.040 |
Why?
|
| Renal Veins | 1 | 2019 | 36 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1420 | 0.040 |
Why?
|
| Anatomic Variation | 1 | 2019 | 2 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 793 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2019 | 101 | 0.040 |
Why?
|
| Neutropenia | 1 | 2020 | 200 | 0.040 |
Why?
|
| Tetrazoles | 1 | 2019 | 68 | 0.040 |
Why?
|
| Biomarkers | 2 | 2018 | 3063 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 106 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 221 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 238 | 0.040 |
Why?
|
| Texas | 2 | 2018 | 3583 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 2091 | 0.040 |
Why?
|
| Comorbidity | 1 | 2023 | 1529 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2018 | 208 | 0.040 |
Why?
|
| Imidazoles | 1 | 2019 | 194 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2006 | 818 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 777 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2019 | 206 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 778 | 0.030 |
Why?
|
| Brain Death | 1 | 2018 | 59 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 183 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2018 | 355 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1248 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 129 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2023 | 3281 | 0.030 |
Why?
|
| Craniocerebral Trauma | 1 | 2017 | 138 | 0.030 |
Why?
|
| Aorta | 1 | 2019 | 539 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 1660 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1151 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2816 | 0.030 |
Why?
|
| Sirolimus | 1 | 2017 | 222 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 996 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 361 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 298 | 0.030 |
Why?
|
| Los Angeles | 1 | 2012 | 15 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2013 | 133 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 112 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 119 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 299 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2016 | 770 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 264 | 0.020 |
Why?
|
| Histocompatibility | 1 | 2010 | 47 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 2009 | 15 | 0.020 |
Why?
|
| Portal System | 1 | 2009 | 32 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2009 | 68 | 0.020 |
Why?
|
| Biomedical Engineering | 1 | 2009 | 28 | 0.020 |
Why?
|
| Pediatrics | 1 | 2019 | 1164 | 0.020 |
Why?
|
| Veterans | 1 | 2021 | 1755 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1214 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 208 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1637 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 71 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2009 | 250 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 2009 | 174 | 0.020 |
Why?
|
| Health Surveys | 1 | 2010 | 239 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 209 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2010 | 255 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 5825 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2010 | 186 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1231 | 0.020 |
Why?
|
| Ampulla of Vater | 1 | 2005 | 16 | 0.020 |
Why?
|
| Pancreatic Ducts | 1 | 2005 | 21 | 0.020 |
Why?
|
| C-Peptide | 1 | 2006 | 113 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 1138 | 0.020 |
Why?
|
| North America | 1 | 2006 | 240 | 0.020 |
Why?
|
| Canada | 1 | 2006 | 288 | 0.010 |
Why?
|
| Duodenum | 1 | 2005 | 99 | 0.010 |
Why?
|
| Insulin | 1 | 2009 | 1202 | 0.010 |
Why?
|
| Pancreas | 1 | 2005 | 218 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3677 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 34072 | 0.000 |
Why?
|